PT - JOURNAL ARTICLE AU - Yamada, Saeko AU - Nagafuchi, Yasuo AU - Wang, Min AU - Ota, Mineto AU - Hatano, Hiroaki AU - Takeshima, Yusuke AU - Okubo, Mai AU - Kobayashi, Satomi AU - Sugimori, Yusuke AU - Nakano, Masahiro AU - Yoshida, Ryochi AU - Hanata, Norio AU - Suwa, Yuichi AU - Tsuchida, Yumi AU - Iwasaki, Yukiko AU - Sumitomo, Shuji AU - Kubo, Kanae AU - Shimane, Kenichi AU - Setoguchi, Keigo AU - Azuma, Takanori AU - Kanda, Hiroko AU - Shoda, Hirofumi AU - Zhang, Xuan AU - Yamamoto, Kazuhiko AU - Ishigaki, Kazuyoshi AU - Okamura, Tomohisa AU - Fujio, Keishi TI - Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance AID - 10.1101/2022.12.21.22283652 DP - 2022 Jan 01 TA - medRxiv PG - 2022.12.21.22283652 4099 - http://medrxiv.org/content/early/2022/12/22/2022.12.21.22283652.short 4100 - http://medrxiv.org/content/early/2022/12/22/2022.12.21.22283652.full AB - Objectives Little is known about the immunology underlying variable treatment response in rheumatoid arthritis (RA). We performed large scale transcriptome analyses of peripheral blood immune cell subsets to identify immune cells that predict treatment resistance.Methods We isolated 18 peripheral blood immune cell subsets of 55 pre-treatment RA patients and 39 healthy controls, and performed RNA sequencing. Transcriptome changes in RA and treatment effects were systematically characterized. Association between immune cell gene modules and treatment resistance was evaluated. We validated predictive value of identified parameters for treatment resistance using quantitative polymerase chain reaction (qPCR) and mass cytometric analysis cohorts. We also characterized the identified population by synovial single cell RNA-seq analysis.Results Immune cells of RA patients were characterized by enhanced interferon and IL6-JAK-STAT3 signaling that demonstrate partial normalization after treatment. A gene expression module of plasmacytoid dendritic cells (pDC) reflecting the expansion of pre-dendritic cells (pre-DC) exhibited strongest association with treatment resistance. Type I interferon signaling was negatively correlated to pre-DC gene expression. qPCR and mass cytometric analysis in independent cohorts validated that the pre-DC associated gene expression and the proportion of pre-DC were significantly higher before treatment in treatment-resistant patients. A cluster of synovial DCs showed both features of pre-DC and proinflammatory conventional DC2s.Conclusions An increase in pre-DC in peripheral blood predicted RA treatment resistance. Pre-DC could have pathophysiological relevance to RA treatment response.What is already known about this subject?Limited information is available about the immune cells that are associated with RA treatment resistance.What does this study add?RA treatment resistance can be predicted by an increase in pre-DC in peripheral blood prior to treatment.The expression of genes reflecting an increase in pre-DC is negatively correlated to the type I interferon signature, which is associated with good therapeutic response.Synovial pre-DC-like cells are proinflammatory cDC2s.How might this impact on clinical practice or future developments?Stratified treatment of RA is possible using pre-DC as a biomarker, and it might be possible to develop new therapies for treatment-resistant RA by targeting pre-DC.Competing Interest StatementY.N., M.Ota., Y Takeshima, and T.O. belong to the Social Cooperation Program, Department of functional genomics and immunological diseases, supported by Chugai Pharmaceutical. K.K. receives speaking fees from Chugai Pharmaceutical. H. K. receives speaking fee and research budget from Chugai Pharmaceutical. K.F. receives consulting honoraria and research support from Chugai Pharmaceutical. S.Y., Y.N., S.S., K.K., and H.S. receives speaking fees from Bristol-Myers Squibb. H. K. receives consulting fee and speaking fee from Bristol-Myers Squibb. K.F. receives speaking fees and research support from Bristol-Myers Squibb.Funding StatementThis research was supported by funding from Chugai, Bristol-Myers Squibb, Japan Agency for Medical Research and Development (AMED) Grant Number JP17ek0109103h0003, and JSPS KAKENHI Grant Number 19K16973.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committees of the University of Tokyo (G-10095, G-10084 and 2019017G).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during this study are available at the National Bioscience Database Center (NBDC) with the study accession code of hum0214. We used publicly available software for the analyses.